QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jul 23, 2019
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a blood test called the QuantiFERON-CMV test can help predict the reactivation of Cytomegalovirus (CMV) in patients with Ulcerative Colitis (UC). CMV can make UC worse, leading to more severe symptoms and making treatment less effective. The goal is to see if this non-invasive blood test can provide useful information about a patient's immune response to CMV, which might help doctors manage the condition better.
To participate in the trial, candidates must be hospitalized due to a flare-up of Ulcerative Colitis and have a positive test for past CMV infection. Participants will need to give their consent and agree to have their blood tested. This trial is currently looking for patients aged between 65 and 74, and it is open to all genders. It's important to know that some individuals, like those who have had certain surgeries or cannot understand the study, may not be eligible. Overall, this study aims to find a simpler way to monitor CMV that could improve care for those dealing with Ulcerative Colitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with seropositive for CytoMegaloVirus (CMV) (IgG+)
- • Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score \> 5 and an endoscopic subscore ≥ 2
- • Social security affiliation
- • Signed informed consent
- Exclusion Criteria:
- • Wardship patient and curatorial patient
- • Patient unable to understand or sign the protocol
- • Colectomy total or partial
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint étienne, , France
Lyon, , France
Patients applied
Trial Officials
Xavier ROBLIN, MD PhD
Principal Investigator
CHU SAINT-ETIENNE
Sylvie PILLET, PhD
Study Director
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials